Federal regulators and a major U.S. drug distributor have quietly yanked certain lots of duloxetine, the generic version of brand name Cymbalta, after lab tests picked up a nitrosamine impurity that experts say could raise cancer risk with long-term exposure. The voluntary recall covers multiple strengths and bottle sizes made by Towa Pharmaceutical in Spain and distributed in the United States by Breckenridge Pharmaceutical.
According to NDClist, which summarizes FDA enforcement records, Breckenridge initiated a voluntary Class II recall that cites “CGMP deviations” and the presence of N-nitroso-duloxetine above the agency’s interim limits. State regulators have pushed out retail-level alerts listing affected NDC codes and lots; for example, the California Board of Pharmacy posted a recall notice that includes the recalled package codes and lot information.
Which packages are involved
Enforcement summaries and state pharmacy notices show the recall reaches across several packaging configurations, including 90-count and 1,000-count bottles in the 51991-747 and 51991-748 NDC families. Multiple lot numbers have been pulled in separate recall events. Regulators report that distribution was nationwide and say the recall is being carried out to the retail level for the listed lots, according to the enforcement record.
Why patients should not abruptly stop
Duloxetine is prescribed for major depressive disorder, generalized anxiety disorder, fibromyalgia and certain types of chronic nerve and musculoskeletal pain, according to the Mayo Clinic. Clinicians generally caution patients not to suddenly stop serotonin-norepinephrine reuptake inhibitors such as duloxetine because of withdrawal symptoms. Anyone worried that their bottle might be part of the recall is urged to contact their prescriber or pharmacist first to talk through safe alternatives or a taper plan.
Why nitrosamines matter
Nitrosamine impurities have been behind a string of recent drug recalls because several chemicals in that family are treated as probable carcinogens, and regulators have set interim acceptable intake levels. The FDA has published guidance and taken actions around nitrosamine impurities, and it advises manufacturers to investigate and remove any lots that exceed the recommended limits.
What the companies say
Local reporting notes that Breckenridge and Towa were not immediately available for comment. Recall notices issued by distributors and state pharmacy boards state that Breckenridge is not aware of adverse events tied to the recalled lots so far. PIX11 and the distributor’s recall materials provide additional detail on specific lots and expiration dates.
How to check your bottle
Look for the NDC and lot number printed on your prescription bottle. Enforcement summaries and state notices list affected codes in the 51991-747 and 51991-748 series along with other package configurations. If your bottle matches an affected lot, do not stop the medication abruptly. Contact your pharmacist or prescriber about replacement options, and call the FDA at 1-888-463-6332 for more information and reporting guidance. NDClist • FDA
Regulators say the immediate risk from a single short exposure is low, but long-term exposure to nitrosamine impurities is the concern that triggered these recalls. For now, the FDA and state pharmacy authorities are urging patients to check lot numbers, talk with their health care providers before making any medication changes, and report any concerns to their pharmacist or the agency.
